Issue · Healthcare

Healthcare

Every healthcare bill, vote, and legislator stance in United States, automatically classified by Maddy, our AI policy reader.

Total bills
11
119th Congress
Top supporter
Darline Graham
100% support rate
Top opponent
Ashley Moody
18% support rate
Ranked legislators
10
5 support · 5 oppose
Key legislators

Who's moving healthcare in United States

Legislators moving healthcare in United States
Legislator Party Stance Support rate Decisive votes
Darline Graham
Darline Graham Senate
R
Strong +
100% 6
AA
Alan Armstrong Senate
R
Strong +
88% 8
Peter Welch
Peter Welch Senate
D
Strong +
82% 22
Ron Wyden
Ron Wyden Senate
D
Support
77% 22
Alex Padilla
Alex Padilla Senate
D
Support
76% 21
Ashley Moody
Ashley Moody Senate
R
Strong −
18% 22
Rick Scott
Rick Scott Senate
R
Strong −
18% 22
Rand Paul
Rand Paul Senate
R
Oppose
23% 22
Brad Knott
Brad Knott House · District 13
R
Oppose
28% 18
Pat Harrigan
Pat Harrigan House · District 10
R
Oppose
28% 18
Showing 11–11 of 11 bills

All healthcare bills

signed · United States · Senate Jul 16, 2025

S 331: HALT Fentanyl Act

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This act permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Under the act, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term). Additionally, the act establishes a new, alternative registration process for certain schedule I research. The act also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration. Finally, the act expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray , a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.
Showing 11 to 11 of 11 bills